Detail akcie Ionis Pharmaceutcls online

Business Summary: Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Ionis Pharmaceuticals Inc revenues decreased 10% to $705.1M. Net loss increased 24% to $453.9M. Revenues reflect WAINUA joint development revenue decrease of 37% to $79.4M, SPINRAZA royalties decrease of 10% to $216.1M. Higher net loss reflects Ionis operations segment loss increase of 34% to $475.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$2.56 to -$3.04.